Boston Scientific Debt to Equity Ratio 2010-2024 | BSX
Current and historical debt to equity ratio values for Boston Scientific (BSX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Boston Scientific debt/equity for the three months ending September 30, 2024 was 0.44.
| Boston Scientific Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $17.12B | $20.96B | 0.82 |
| 2024-06-30 | $16.50B | $20.61B | 0.80 |
| 2024-03-31 | $16.50B | $20.17B | 0.82 |
| 2023-12-31 | $15.61B | $19.53B | 0.80 |
| 2023-09-30 | $14.91B | $19.13B | 0.78 |
| 2023-06-30 | $15.12B | $18.49B | 0.82 |
| 2023-03-31 | $14.78B | $18.11B | 0.82 |
| 2022-12-31 | $14.90B | $17.57B | 0.85 |
| 2022-09-30 | $14.31B | $17.64B | 0.81 |
| 2022-06-30 | $14.94B | $17.25B | 0.87 |
| 2022-03-31 | $15.60B | $16.74B | 0.93 |
| 2021-12-31 | $15.61B | $16.62B | 0.94 |
| 2021-09-30 | $15.42B | $16.46B | 0.94 |
| 2021-06-30 | $15.23B | $15.94B | 0.96 |
| 2021-03-31 | $15.18B | $15.72B | 0.97 |
| 2020-12-31 | $15.45B | $15.33B | 1.01 |
| 2020-09-30 | $15.28B | $15.56B | 0.98 |
| 2020-06-30 | $15.21B | $15.62B | 0.97 |
| 2020-03-31 | $16.31B | $13.80B | 1.18 |
| 2019-12-31 | $16.69B | $13.88B | 1.20 |
| 2019-09-30 | $17.06B | $9.70B | 1.76 |
| 2019-06-30 | $14.88B | $9.43B | 1.58 |
| 2019-03-31 | $14.57B | $9.23B | 1.58 |
| 2018-12-31 | $12.27B | $8.73B | 1.41 |
| 2018-09-30 | $12.09B | $8.29B | 1.46 |
| 2018-06-30 | $11.87B | $7.74B | 1.53 |
| 2018-03-31 | $12.17B | $7.03B | 1.73 |
| 2017-12-31 | $12.03B | $7.01B | 1.72 |
| 2017-09-30 | $11.05B | $7.59B | 1.46 |
| 2017-06-30 | $11.15B | $7.24B | 1.54 |
| 2017-03-31 | $10.89B | $7.05B | 1.54 |
| 2016-12-31 | $11.36B | $6.73B | 1.69 |
| 2016-09-30 | $11.22B | $6.48B | 1.73 |
| 2016-06-30 | $11.62B | $6.22B | 1.87 |
| 2016-03-31 | $11.26B | $6.46B | 1.74 |
| 2015-12-31 | $11.81B | $6.32B | 1.87 |
| 2015-09-30 | $11.81B | $6.41B | 1.84 |
| 2015-06-30 | $10.54B | $6.58B | 1.60 |
| 2015-03-31 | $9.97B | $6.50B | 1.53 |
| 2014-12-31 | $10.57B | $6.46B | 1.64 |
| 2014-09-30 | $10.02B | $6.70B | 1.50 |
| 2014-06-30 | $9.93B | $6.54B | 1.52 |
| 2014-03-31 | $9.80B | $6.53B | 1.50 |
| 2013-12-31 | $10.03B | $6.54B | 1.53 |
| 2013-09-30 | $10.35B | $6.56B | 1.58 |
| 2013-06-30 | $10.39B | $6.60B | 1.57 |
| 2013-03-31 | $10.26B | $6.50B | 1.58 |
| 2012-12-31 | $10.28B | $6.87B | 1.50 |
| 2012-09-30 | $10.07B | $6.83B | 1.48 |
| 2012-06-30 | $10.09B | $7.73B | 1.31 |
| 2012-03-31 | $9.79B | $11.40B | 0.86 |
| 2011-12-31 | $9.94B | $11.35B | 0.88 |
| 2011-09-30 | $9.98B | $11.52B | 0.87 |
| 2011-06-30 | $10.02B | $11.54B | 0.87 |
| 2011-03-31 | $10.70B | $11.37B | 0.94 |
| 2010-12-31 | $10.83B | $11.30B | 0.96 |
| 2010-09-30 | $11.45B | $11.04B | 1.04 |
| 2010-06-30 | $12.13B | $10.89B | 1.11 |
| 2010-03-31 | $12.07B | $10.78B | 1.12 |
| 2009-12-31 | $12.88B | $12.30B | 1.05 |
| 2009-09-30 | $12.93B | $13.30B | 0.97 |
| 2009-06-30 | $12.78B | $13.41B | 0.95 |
| 2009-03-31 | $12.83B | $13.28B | 0.97 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $131.097B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $198.127B | 25.27 |
| Stryker (SYK) | United States | $138.991B | 31.32 |
| EssilorLuxottica (ESLOY) | France | $109.895B | 0.00 |
| Medtronic (MDT) | Ireland | $103.904B | 15.43 |
| Haleon (HLN) | United Kingdom | $43.864B | 28.50 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.859B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $36.052B | 18.70 |
| ResMed (RMD) | United States | $34.830B | 28.62 |
| Terumo (TRUMY) | Japan | $28.875B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.602B | 18.07 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.325B | 13.58 |
| Insulet (PODD) | United States | $18.698B | 74.46 |
| Baxter (BAX) | United States | $15.062B | 9.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.781B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.800B | 39.43 |
| Bio-Rad Laboratories (BIO) | United States | $9.168B | 31.16 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.208B | 14.42 |
| Prestige Consumer Healthcare (PBH) | United States | $3.889B | 19.34 |
| ICU Medical (ICUI) | United States | $3.840B | 36.56 |
| Haemonetics (HAE) | United States | $3.789B | 18.49 |
| Perrigo (PRGO) | Ireland | $3.513B | 10.34 |
| Envista Holdings (NVST) | United States | $3.218B | 23.97 |
| QuidelOrtho (QDEL) | United States | $3.016B | 19.41 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.609B | 30.10 |
| LeMaitre Vascular (LMAT) | United States | $2.071B | 50.34 |
| Green Thumb Industries (GTBIF) | United States | $1.678B | 29.37 |
| AtriCure (ATRC) | United States | $1.498B | 0.00 |
| InMode (INMD) | Israel | $1.434B | 8.63 |
| AdaptHealth (AHCO) | United States | $1.383B | 9.88 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.356B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.271B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.968B | 0.00 |
| Owens & Minor (OMI) | United States | $0.965B | 7.54 |
| CeriBell (CBLL) | United States | $0.964B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.879B | 15.49 |
| Evolus (EOLS) | United States | $0.690B | 0.00 |
| Omeros (OMER) | United States | $0.597B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.594B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.584B | 25.75 |
| Surmodics (SRDX) | United States | $0.568B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.452B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.439B | 0.00 |
| Quanterix (QTRX) | United States | $0.403B | 0.00 |
| ZimVie (ZIMV) | United States | $0.375B | 31.63 |
| Biote (BTMD) | United States | $0.331B | 7.26 |
| Valneva SE (VALN) | France | $0.324B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.311B | 29.56 |
| Canopy Growth (CGC) | Canada | $0.308B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.294B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.20 |
| Zynex (ZYXI) | United States | $0.263B | 55.00 |
| High Tide (HITI) | Canada | $0.242B | 100.33 |
| Aurora Cannabis (ACB) | Canada | $0.234B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.29 |
| Sanuwave Health (SNWV) | United States | $0.201B | 2.82 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.197B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.190B | 0.00 |
| Brainsway (BWAY) | Israel | $0.174B | 92.40 |
| FitLife Brands (FTLF) | United States | $0.145B | 18.17 |
| Jin Medical (ZJYL) | China | $0.133B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.124B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.107B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.81 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| Veru (VERU) | United States | $0.095B | 0.00 |
| Exagen (XGN) | United States | $0.091B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.051B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.044B | 0.00 |
| ImmuCell (ICCC) | United States | $0.039B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.005B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.74 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |